Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban versus VKA for anticoagulation in atrial fibrillation catheter ablation
NL-OMON45248Phase 3Withdrawn
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) comparing Edoxaban study arm with VKA study arm (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Planned start Jan 2017; status: withdrawn.
02
Drugs
edoxabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON45248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45248.